Figure 1.

AAT treatment improves islet survival and function in a syngeneic mouse intraportal islet transplantation model. A: Kaplan-Meier analysis shows significantly higher percentages of PT normoglycemia in diabetic mice that received AAT (2 mg/kg) Q2D or Q3D compared with control (Ctrl), which received vehicle. B: AAT-treated mice reached normoglycemia faster than control mice. C: IVGTT shows that AAT treatment (Q2D) enhances blood glucose disposal 30 days after transplantation. Inset, AUC of IVGTT. D: Serum concentrations of human AAT before the last dose in each group (n = 8–9 in each group). Data are expressed as mean ± SD. *P < 0.05, **P < 0.01 by Student t test.